Author/Authors :
Azarfarin, Rasoul Cardio-Oncology Research Center - Rajaie Cardiovascular Research Center - Iran University of Medical Sciences, Tehran, Iran , Ziyaeifard, Mohsen Cardio-Oncology Research Center - Rajaie Cardiovascular Research Center - Iran University of Medical Sciences, Tehran, Iran , Alizadehasl, Azin Cardio-Oncology Research Center - Rajaie Cardiovascular Research Center - Iran University of Medical Sciences, Tehran, Iran , Roudini, Kamran 2Department of Internal Medicine - Cancer Institute - Imam Khomeini Hospital Complex - Tehran University of Medical Sciences, Tehran, Iran , Hadipourzadeh, Fatemehshima Rajaie Cardiovascular Research Center - Iran University of Medical Sciences, Tehran, Iran
Abstract :
Introduction: One of the conditions leading to hemolysis in patients with artificial metallic heart valves is valvular dysfunction. In case of symptomatic hemolysis, a blood transfusion may be needed along with standard treatments. Inattention to the di erential diagnosis of hemolysis and making decisions based on causes that are more obvious can lead to incorrect approaches.
Case Presentation: In this case report, we presented a case with a previously undiagnosed rare blood group (positive antibody anti-E, anti-c, anti-Kell), undergoing reoperation of mitral valve replacement (MVR), who developed severe hemolysis and subsequent acute renal failure secondary to incompatible blood transfusion and required hemodialysis.
Conclusions: In this patient, hemolysis was solely attributed to mitral valve dysfunction. By timely diagnosis of the subtype of her blood group and appropriate decision-making during surgery, adverse blood transfusion outcomes were prevented.